Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-02

Study Completion Date

2025-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of femoral vein wall thickness and inflammatory indices in patients with Behcet disease and assessment of their relation to the disease activity and related some clinical manifestations

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Behçet

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients fulfill the International Criteria for Behcet's Disease (ICBD)
* Age above 18 years old
* Patients cooperative and can answer questions
* Patients who are able and willing to give informed consent

Exclusion Criteria

* Other rheumatological and vascular diseases
* Patients with abnormal hepatic or renal function tests , hyperlipidemia and impaired coagulation tests
* Patients with hypertension , diabetes mellitus , malignant and active infectious diseases
* Patients who are using aspirin and other platelet active drygs during the previous 6 months
* patients who are not able and willing to give written consent

Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Engy Louis Fawzy

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag university

Sohag, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Engy L Fawzy

Role: CONTACT

Phone: 01282665433

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Engy L Fawzy, Resident

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med--24-11-03MS

Identifier Type: -

Identifier Source: org_study_id